Clinical Trial Update: Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of the PET imaging agent [18F]NAV4694 in subjects with probable Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [18F]NAV4694 (NAV4694)

Snippet

Sponsor: Navidea Biopharmaceuticals | Conditions: Alzheimer Disease | Phase 2 | Status: UNKNOWN